ARCA biopharma, Inc. (NASDAQ:ABIO) Major Shareholder Henderson Group Plc Janus Buys 47,492 Shares

ARCA biopharma, Inc. (NASDAQ:ABIO) major shareholder Henderson Group Plc Janus bought 47,492 shares of the company’s stock in a transaction that occurred on Monday, July 8th. The shares were purchased at an average price of $3.46 per share, with a total value of $164,322.32. Following the transaction, the insider now directly owns 1,724,395 shares in the company, valued at $5,966,406.70. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Henderson Group Plc Janus also recently made the following trade(s):

• On Wednesday, July 10th, Henderson Group Plc Janus bought 55,463 shares of ARCA biopharma stock. The shares were purchased at an average price of $3.46 per share, with a total value of $191,901.98.
• On Friday, July 5th, Henderson Group Plc Janus acquired 28,326 shares of ARCA biopharma stock. The stock was bought at an average price of $3.43 per share, with a total value of $97,158.18.
• On Wednesday, July 3rd, Henderson Group Plc Janus bought 166,042 shares of ARCA biopharma stock. The stock was acquired at an average cost of $3.55 per share, for a total transaction of $589,449.10.

ARCA biopharma Trading Up 0.9 %

Shares of NASDAQ ABIO traded up $0.03 during midday trading on Friday, reaching $3.35. The company’s stock had a trading volume of 14,055 shares, compared to its average volume of 713,609. ARCA biopharma, Inc. has a fifty-two week low of $1.56 and a fifty-two week high of $4.49. The stock has a market capitalization of $48.61 million, a price-to-earnings ratio of -7.98 and a beta of 0.90. The stock has a 50 day simple moving average of $3.43 and a 200-day simple moving average of $2.54.

ARCA biopharma (NASDAQ:ABIO) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on shares of ARCA biopharma in a research note on Wednesday, May 22nd. They set a “sell” rating on the stock.

Hedge Funds Weigh In On ARCA biopharma

An institutional investor recently bought a new position in ARCA biopharma stock. abrdn plc acquired a new position in shares of ARCA biopharma, Inc. (NASDAQ:ABIO) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 32,461 shares of the biopharmaceutical company’s stock, valued at approximately $55,000. 56.44% of the stock is owned by institutional investors and hedge funds.

ARCA biopharma Company Profile

ARCA biopharma, Inc, a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure.